Insomnia Treatment and EMA (ecological Momentary Assessment) Outcomes

Outcome assessments are conducted at two weeks while participants are on study treatment or placebo and include self-report questionnaires and cognitive testing administered by computer.

Participants will wear an actiwatch for 16 days while completing EMA surveys. It has a small sensor that tracks motion.

FDA approved which is an orexin receptor antagonist indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

An inactive substance that looks like the drug or treatment being tested.